Preterm Birth and PROM Testing Market Size & Growth Forecast 2027–2036, By Segments (Application, Test Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Preterm Birth and PROM Testing Market size was estimated at USD 1.8 billion in 2026 and is projected to grow at a 8.27% CAGR from 2027 to 2036, exceeding USD 3.98 billion by 2036. The industry revenue for 2027 is assessed at USD 1.93 billion.
Get more details on this report
Request Free Sample ReportPreterm Birth and PROM Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America holds a 40.60% share in 2026, supported by structured prenatal care systems, broad diagnostic access, and routine risk-based screening integrated into obstetric decision-making pathways.
- Asia Pacific is growing at a 9.49% CAGR due to improving maternal healthcare access, expanded prenatal screening capacity, and greater integration of diagnostic testing into routine antenatal care.
Segment Momentum
- Ultrasound accounted for 33.39% of the market in 2026 due to its established role in obstetric evaluation and seamless integration into standard prenatal and emergency care workflows.
- PAMG-1 Immunoassay is the fastest-growing test type because it provides more specific confirmation of membrane rupture, helping clinicians make faster decisions and reduce diagnostic uncertainty in PROM cases.
Market Expansion Drivers
- Increasing maternal age and pregnancy complications driving demand for early risk detection testing.
- Expanding adoption of point-of-care diagnostics improving rapid detection of fetal membrane rupture risks.
- Government-funded maternal health screening programs expanding access to prenatal diagnostic testing.
Leading Market Participants
- Leading players in the preterm birth and PROM testing market include Hologic, Inc. (United States), QIAGEN N.V. (Germany), Abbott Laboratories (United States), CooperSurgical, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Laborie Medical Technologies (Canada), Medix Biochemica (Finland), Biosynex SA (France), NX Prenatal Inc. (United States), Thermo Fisher Scientific Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.8 billion
- 2027 Estimated Market Size: USD 1.93 billion.
- Projected Market Size: USD 3.98 billion by 2036
- Growth Forecast: 8.27% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Preterm Labor (Application) | Ultrasound (Test Type)
- Emerging Opportunity Segment: PROM (Application) | PAMG-1 Immunoassay (Test Type)
Market Growth Drivers and Industry Trends
Increasing maternal age and pregnancy complications driving demand for early risk detection testing
Rising maternal age and the increasing prevalence of pregnancy-related complications are creating greater demand for timely assessment of conditions associated with preterm delivery, supporting preterm birth and PROM testing market growth. Women with higher-risk pregnancies may require closer monitoring to identify signs associated with premature labor or premature rupture of membranes, allowing healthcare professionals to evaluate risks and determine appropriate management. Diagnostic testing provides additional clinical information alongside physical assessment, supporting earlier recognition of membrane rupture and other conditions that can affect pregnancy outcomes.
Expanding adoption of point-of-care diagnostics improving rapid detection of fetal membrane rupture risks
The availability of rapid diagnostic technologies is strengthening preterm birth and PROM testing market growth by enabling clinicians to evaluate suspected membrane rupture closer to the point of patient care. Point-of-care tests can provide results during clinical assessment, reducing dependence on centralized laboratory workflows and helping healthcare professionals make timely decisions regarding observation, treatment, or further evaluation. Faster access to diagnostic information is particularly valuable in maternity settings where delays in identifying membrane rupture can complicate pregnancy management and influence decisions around maternal and fetal care.
Government-funded maternal health screening programs expanding access to prenatal diagnostic testing
Public investment in maternal and prenatal healthcare is increasing access to screening and diagnostic services, thereby supporting preterm birth and PROM testing market growth across healthcare systems. Government-backed maternal health programs can strengthen routine pregnancy monitoring, improve availability of diagnostic services, and encourage earlier identification of complications among women who may otherwise have limited access to specialized testing. Broader screening coverage also enables healthcare providers to incorporate diagnostic assessments into standardized prenatal care pathways, particularly in regions where maternal health infrastructure is being expanded.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing maternal age and pregnancy complications driving demand for early risk detection testing | 2.00% | High | North America, Asia Pacific | High | Near Term |
|
Explore Growth Opportunities Request Free Sample Report |
|||||
| Expanding adoption of point-of-care diagnostics improving rapid detection of fetal membrane rupture risks | 1.80% | High | North America, Europe | High | Near Term |
|
Explore Growth Opportunities Request Free Sample Report |
|||||
| Government-funded maternal health screening programs expanding access to prenatal diagnostic testing | 1.50% | High | Asia Pacific, Latin America | Emerging | Mid Term |
|
Explore Growth Opportunities Request Free Sample Report |
Regional Demand Dynamics
North America (Largest Region)
North America dominated the preterm birth and PROM testing market with a 40.60% share in 2026, supported by well-developed maternal healthcare systems and broad availability of advanced diagnostic services. The region benefits from established prenatal care practices, greater awareness of complications associated with premature delivery, and routine use of diagnostic approaches for identifying risks related to preterm birth and premature rupture of membranes. Strong clinical emphasis on early risk assessment and timely intervention further supports demand for testing, while sophisticated hospital infrastructure and established obstetric care pathways facilitate the integration of diagnostic technologies into maternal healthcare.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region as improvements in maternal healthcare access and expanding diagnostic infrastructure increase the adoption of testing for preterm birth and PROM. Greater awareness of pregnancy-related complications is encouraging earlier engagement with prenatal services, while healthcare modernization is improving the availability of specialized obstetric diagnostics. Increasing demand for better pregnancy monitoring, particularly in rapidly developing healthcare systems, is also supporting market opportunities. Continued strengthening of hospital capabilities and broader adoption of evidence-based maternal care are expected to contribute to greater utilization of these tests across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Evidence-Based Prenatal CareGermany prioritizes clinically validated preterm birth and PROM testing that aligns with standardized obstetric care protocols. Healthcare institutions focus on diagnostic accuracy, efficient laboratory workflows, and reliable testing methods to support informed maternal care decisions.
France 🇫🇷
Preventive Obstetric AssessmentFrance promotes preterm birth and PROM testing as part of preventive maternal healthcare strategies for high-risk pregnancies. French healthcare providers seek reliable diagnostic tools that improve clinical confidence while supporting coordinated prenatal care across healthcare settings.
Italy 🇮🇹
Specialized Maternity SupportItaly focuses on strengthening diagnostic capabilities for preterm birth and PROM assessment within specialized obstetric centers. Healthcare professionals increasingly utilize accurate testing methods that facilitate timely clinical intervention and improve pregnancy management practices.
Japan 🇯🇵
Precision Pregnancy MonitoringJapan incorporates preterm birth and PROM testing into high-quality prenatal monitoring programs, emphasizing early detection of pregnancy complications. Healthcare providers favor dependable diagnostic technologies that minimize unnecessary interventions while supporting individualized maternal care.
South Korea 🇰🇷
Hospital Diagnostic AdoptionSouth Korea continues expanding the use of preterm birth and PROM testing within hospital-based maternity services. Clinical laboratories prioritize rapid turnaround times and advanced diagnostic platforms that strengthen obstetric decision-making and patient management.
United States 🇺🇸
Maternal Diagnostics IntegrationThe U.S. emphasizes early-risk assessment through wider integration of preterm birth and PROM testing into prenatal care pathways. Healthcare providers increasingly adopt rapid and clinically validated diagnostic solutions that support timely intervention and improve pregnancy management decisions.
Segment Leadership and Growth Trends
Preterm Birth and PROM Testing Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Preterm Labor (Largest Segment) vs PROM (Fastest-Growing Segment)
Preterm labor represented the largest application segment in the preterm birth and PROM testing market in 2026, accounting for 44.94% share. Its leading position is supported by the clinical importance of identifying women at risk of premature delivery and enabling timely intervention. Testing for preterm labor assists healthcare professionals in evaluating symptoms and making informed decisions regarding monitoring, treatment, and delivery management. Growing emphasis on maternal and fetal health, together with the need for early clinical assessment, continues to sustain demand for diagnostic solutions in this application.
The PROM application segment is experiencing the fastest growth as healthcare providers place greater emphasis on the early identification of membrane rupture and associated pregnancy risks. Accurate detection of premature rupture of membranes can support appropriate clinical management and help reduce complications associated with delayed diagnosis. Increasing awareness of maternal care protocols and the adoption of rapid diagnostic approaches are strengthening the role of PROM testing within obstetric care.
Test Type Segment Analysis: Ultrasound (Largest Segment) vs PAMG-1 Immunoassay (Fastest-Growing Segment)
Ultrasound held the largest share of the preterm birth and PROM testing market in 2026, accounting for 33.39% share. Its established role in prenatal assessment and its ability to provide non-invasive visualization of maternal and fetal conditions support widespread clinical use. Ultrasound can complement other diagnostic evaluations by providing information relevant to fetal development, cervical assessment, and pregnancy complications. Its established presence across obstetric care settings and broad clinical utility continue to underpin its leading position.
PAMG-1 immunoassay is the fastest-growing test type, supported by increasing demand for more targeted diagnostic approaches to identify premature rupture of membranes. Its role in detecting pregnancy-related biomarkers can help clinicians distinguish membrane rupture from other causes of fluid leakage, supporting more informed treatment decisions. Growing preference for rapid and clinically focused testing methods is contributing to increased adoption of PAMG-1-based diagnostic solutions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | PROM, Preterm Labor, Chorioamnionitis | Preterm Labor | PROM |
| Test Type | Pelvic Exam, Ultrasound, Biochemical Markers, Uterine Monitoring, Nitazine Test, Ferning Test, Pooling, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN), Others | Ultrasound | PAMG-1 Immunoassay |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the preterm birth and PROM testing market:
1. Hologic Inc. (United States)
2. QIAGEN N.V. (Germany)
3. Abbott Laboratories (United States)
4. CooperSurgical Inc. (United States)
5. F. Hoffmann-La Roche Ltd (Switzerland)
6. Laborie Medical Technologies (Canada)
7. Medix Biochemica (Finland)
8. Biosynex SA (France)
9. NX Prenatal Inc. (United States)
10. Thermo Fisher Scientific Inc. (United States)
The preterm birth and PROM testing market is witnessing increased innovation focused on improving diagnostic accuracy and early risk assessment for maternal healthcare management. Manufacturers are introducing rapid testing solutions and biomarker-based diagnostic technologies designed to support timely clinical intervention. Rising emphasis on preventive prenatal care and improved patient outcomes is further influencing market competitiveness.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Hologic Inc. (United States) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| Abbott Laboratories (United States) | |||||||
| CooperSurgical Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Laborie Medical Technologies (Canada) | |||||||
| Medix Biochemica (Finland) | |||||||
| Biosynex SA (France) | |||||||
| NX Prenatal Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Mirvie | May-25 | Mirvie launched Encompass, a predictive blood test that analyzes cell-free RNA to identify personalized preeclampsia risk months before clinical symptoms manifest. This diagnostic solution represents an advancement in prenatal monitoring, moving toward proactive, molecular-based risk assessment for pregnancy-related complications. |
| Roche | Feb-25 | Roche received FDA 510(k) clearance for its Elecsys sFlt-1/PlGF ratio test, a diagnostic tool designed for the assessment of preeclampsia risk. The regulatory approval enables clinical adoption of this biomarker-based assay, providing physicians with standardized, actionable data for managing high-risk pregnancies and identifying patients requiring closer monitoring. |
| Qiagen | Sep-24 | Qiagen expanded the utility of its QIAcuity digital PCR platform by introducing over 100 new assays, including specialized applications for maternal health. The move integrates high-precision digital PCR capabilities into clinical pregnancy monitoring, allowing for more sensitive and accurate quantification of biomarkers relevant to maternal and fetal health outcomes. |
| Novocuff | Jul-24 | Novocuff secured USD 26 million in funding to accelerate the development of its medical device platform aimed at preterm birth prevention. This capital infusion supports ongoing clinical and commercialization efforts to introduce a mechanical intervention for managing cervical insufficiency, expanding the landscape of therapeutic options beyond diagnostic testing. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Preterm Birth and PROM Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Healthcare Setting | Hospitals, Maternal-Fetal Medicine Centers, Diagnostic Laboratories, Physician Offices |
| Patient Risk Category | High-Risk Pregnancy, Moderate-Risk Pregnancy, Low-Risk Pregnancy |
| Gestational Age Group | Less Than 28 Weeks, 28–32 Weeks, 33–36 Weeks, 37 Weeks and Above |
Preterm Birth and PROM Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Maternal Healthcare Screening Pathway Assessment |
|
| High-Risk Pregnancy Population Opportunity Mapping |
|
| Point-of-Care Testing Commercialization Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the preterm birth and PROM testing market?
What are the growth projections for the preterm birth and PROM testing industry?
How is increasing maternal age driving demand for early risk detection in preterm birth and PROM testing?
Why is point-of-care testing accelerating adoption in PROM diagnostic pathways?
Why does Ultrasound remain the largest test type in the preterm birth and PROM testing market?
What is driving the growth of PAMG-1 Immunoassay in the preterm birth and PROM testing market?
Why does North America dominate the preterm birth and PROM testing market?
What factors are supporting Asia Pacific’s growth in this market?
Which companies are driving growth in the preterm birth and PROM testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization